Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine (CYC682) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute

Read the full 317 word article

How to gain access

Continue reading with a
two-week free trial.